Correlating phenotype and genotype in the periodic paralyses
TM Miller, MR Dias da Silva, HA Miller, H Kwiecinski… - Neurology, 2004 - AAN Enterprises
TM Miller, MR Dias da Silva, HA Miller, H Kwiecinski, JR Mendell, R Tawil, P McManis…
Neurology, 2004•AAN EnterprisesBackground: Periodic paralyses and paramyotonia congenita are rare disorders causing
disabling weakness and myotonia. Mutations in sodium, calcium, and potassium channels
have been recognized as causing disease. Objective: To analyze the clinical phenotype of
patients with and without discernible genotype and to identify other mutations in ion channel
genes associated with disease. Methods: The authors have reviewed clinical data in
patients with a diagnosis of hypokalemic periodic paralysis (56 kindreds, 71 patients) …
disabling weakness and myotonia. Mutations in sodium, calcium, and potassium channels
have been recognized as causing disease. Objective: To analyze the clinical phenotype of
patients with and without discernible genotype and to identify other mutations in ion channel
genes associated with disease. Methods: The authors have reviewed clinical data in
patients with a diagnosis of hypokalemic periodic paralysis (56 kindreds, 71 patients) …
Background: Periodic paralyses and paramyotonia congenita are rare disorders causing disabling weakness and myotonia. Mutations in sodium, calcium, and potassium channels have been recognized as causing disease.
Objective: To analyze the clinical phenotype of patients with and without discernible genotype and to identify other mutations in ion channel genes associated with disease.
Methods: The authors have reviewed clinical data in patients with a diagnosis of hypokalemic periodic paralysis (56 kindreds, 71 patients), hyperkalemic periodic paralysis (47 kindreds, 99 patients), and paramyotonia congenita (24 kindreds, 56 patients). For those patients without one of the classically known mutations, the authors analyzed the entire coding region of the SCN4A, KCNE3, and KCNJ2 genes and portions of the coding region of the CACNA1S gene in order to identify new mutations.
Results: Mutations were identified in approximately two thirds of kindreds with periodic paralysis or paramyotonia congenita. The authors found differences between the disorders and between those with and without identified mutations in terms of age at onset, frequency of attacks, duration of attacks, fixed proximal weakness, precipitants of attacks, myotonia, electrophysiologic studies, serum potassium levels, muscle biopsy, response to potassium administration, and response to treatment with acetazolamide.
Conclusions: Hypokalemic periodic paralysis, hyperkalemic periodic paralysis, and paramyotonia congenita may be distinguished based on clinical data. This series of 226 patients (127 kindreds) confirms some clinical features of this disorder with notable exceptions: In this series, patients without mutations had a less typical clinical presentation including an older age at onset, no changes in diet as a precipitant, and absence of vacuolar myopathy on muscle biopsy.
American Academy of Neurology